Merck KGaA Just Dropped $11 Billion on a Company Most People Never Heard Of
Merck KGaA is paying $11.3 billion in cash for Bio-Techne, a lab tools company most people outside biotech have never heard of. The deal reveals a quiet arms race among life science giants racing to control the picks and shovels of drug discovery.
The Biggest Shopping Spree in Lab Tools Just Got Bigger
Somewhere in a Minneapolis office park sits a company that makes proteins, antibodies, and lab reagents you've probably never thought about. Bio-Techne doesn't have the name recognition of Pfizer or Moderna. It doesn't make blockbuster drugs or headline-grabbing vaccines. What it does make is the stuff that everyone else needs to discover those drugs in the first place.
And Merck KGaA just agreed to buy it for $11.3 billion in cash.
The German conglomerate (not to be confused with its American namesake Merck & Co.) will pay $73 per share to acquire Bio-Techne, a price that represents a 36% premium over the stock's one-month average trading price. The deal, if it clears regulatory hurdles, is expected to close in late 2026 or early 2027.
Think of it this way: if drug development is a kitchen, Bio-Techne makes the pots, pans, and ingredients. Every biotech company running experiments on cancer, gene therapy, or autoimmune diseases needs high-quality reagents, proteins, and diagnostic tools. Bio-Techne sells those by the truckload, pulling in $1.2 billion in revenue last fiscal year.
Why Merck KGaA Is Writing a Very Large Check
Merck KGaA has been on this path for over a decade. The company bought Millipore in 2010 for about $7.2 billion, then followed up with the massive $17 billion Sigma-Aldrich acquisition in 2015. Those two deals built MilliporeSigma into one of the world's biggest life science suppliers. Bio-Techne is the next chapter.
The strategic logic isn't complicated. Bio-Techne is strong in areas where Merck wants to grow: protein analysis, cell culture tools, and specialty diagnostics. About 72% of Bio-Techne's revenue comes from its Protein Sciences segment, which sells the core reagents and instruments that researchers use daily. The remaining 28% comes from Diagnostics and Spatial Biology, a division focused on newer technologies like liquid biopsy (blood-based cancer detection) and tissue-level molecular profiling.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Merck expects to squeeze out roughly €140 million in annual cost savings by year three after closing. The deal should boost Merck's sales growth and profit margins right away, with earnings-per-share improvements kicking in by the third year.
For Merck, this is also about timing. Life science tools stocks have been beaten up. Bio-Techne's shares had fallen 35% over five years before the offer landed. That kind of weakness gives a well-capitalized buyer like Merck the chance to pick up quality assets at prices that would have been unthinkable a few years ago.
Wall Street's Verdict: Fair Price, Smart Move
Analysts aren't calling this a steal, but they're not calling it reckless either.
Before the deal was announced, the highest price target on Bio-Techne from major sell-side firms was $65 per share (from TD Cowen). Piper Sandler had a $60 per share price target, while RBC Capital had it at $61. So Merck's $73 offer sits well above where Wall Street thought the stock was headed on its own.
Bio-Techne's board unanimously approved the deal and recommended shareholders vote yes. That's not surprising given the context. Long-term shareholders were nursing painful losses; anyone who bought five years ago was sitting on a roughly 50% decline. Activist investor Ananym Capital Management had been pushing Bio-Techne to explore a sale, arguing the company was underperforming its peers. The $73 all-cash offer essentially hands those frustrated shareholders a clean exit above anyone's price target.
Merck KGaA's own stock barely budged on the news, ticking up about half a percent. In M&A terms, that's a thumbs-up from investors. When an acquirer's stock drops on deal news, it usually signals the market thinks they overpaid. A flat-to-positive reaction means investors trust the math.
The Arms Race Nobody's Talking About
This deal doesn't exist in a vacuum. There's a quiet war happening in life science tools, and the biggest players are gobbling up smaller companies at a steady clip.
Thermo Fisher bought Olink (a proteomics platform company) for $3.1 billion and The Binding Site (specialty diagnostics) for approximately $2.6 billion. Danaher scooped up Abcam, a major antibody supplier, for $5.7 billion. Now Merck KGaA is making its own move with Bio-Techne.
The pattern is clear: all three giants are racing to control the tools and consumables that power modern biotech research. Reagents, antibodies, protein analysis platforms, diagnostic kits; these are the picks and shovels of the biotech gold rush. And just like in an actual gold rush, selling picks and shovels is often more profitable (and more predictable) than mining for gold yourself.
The consolidation is accelerating, too. After a slow 2024, global healthcare M&A activity rebounded significantly in 2025. Advisory firms expect the pace to keep climbing through 2026 as interest rates stabilize and strategic buyers deploy their cash piles.
What Bio-Techne Actually Makes (And Why It Matters)
Bio-Techne isn't just one product line. It's a collection of specialized brands that researchers across the world rely on daily.
R&D Systems sells proteins, cytokines (signaling molecules that control immune responses), and ELISA kits (a common lab test for measuring specific proteins). Novus Biologicals focuses on antibodies. ProteinSimple makes automated instruments for analyzing proteins. Exosome Diagnostics develops blood-based cancer tests. There are others, each serving a niche but essential corner of the research ecosystem.
Of Bio-Techne's $1.2 billion in fiscal 2025 revenue, roughly 80% came from consumables: the reagents, kits, and controls that labs burn through and reorder constantly.
That consumables-heavy mix is exactly what makes Bio-Techne attractive. Instruments are a one-time sale; reagents are recurring revenue. Once a lab standardizes on your proteins and antibodies, switching costs are high. It's the razor-and-blades model, applied to science.
The Fine Print (And the Risks)
The deal still needs to clear two gates: a Bio-Techne shareholder vote and regulatory approval from competition authorities in multiple jurisdictions. Neither is expected to be a dealbreaker, but the projected closing window of late 2026 to early 2027 suggests the regulatory review won't be quick.
Merck plans to fund the purchase with a mix of cash on hand and new debt, and has specifically committed to maintaining its investment-grade credit rating. That's corporate-speak for "we can afford this without putting the company at risk."
The bigger question is whether Merck can actually extract those €140 million in synergies and integrate a company with seven distinct brands and two very different business segments. History offers some comfort: Merck successfully absorbed both Millipore and Sigma-Aldrich, transforming its Life Science division into a global powerhouse in the process.
But history also shows that life science tools integration is tricky. The cultures are different, the customer relationships are personal, and the product catalogs are enormous. Merck will need to execute carefully to avoid disrupting the very thing that makes Bio-Techne valuable: the trust that thousands of researchers place in its products every single day.
Clinical & Regulatory
4 min read
Trodelvy Just Jumped the Line in Breast Cancer Treatment
The FDA just moved Gilead's Trodelvy from last-resort to first-choice in triple-negative breast cancer, the deadliest breast cancer subtype. It's a seismic shift for patients, a multi-billion-dollar opportunity for Gilead, and a surprisingly friendly outcome for Merck's Keytruda.
